A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Trial Profile

A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Dinaciclib (Primary) ; Alemtuzumab; Alemtuzumab; Bortezomib
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 09 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 25 Apr 2012 Actual patient number (8) added as reported by ClinicalTrials.gov.
    • 25 Apr 2012 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top